NeoPharm's Cintredekin Besudotox Well-Tolerated in Newly Diagnosed Malignant Glioma Patients.
Business Wire › April 25, 2006
Linked as:
Extract
NeoPharm's Cintredekin Besudotox Well-Tolerated in Newly Diagnosed Malignant Glioma Patients.
SAN FRANCISCO -- NeoPharm, Inc. (Nasdaq:NEOL):
--Phase I Study Confirms Combination Therapy that Includes Cintredekin Besudotox May Be An Option For This Patient Population NeoPharm, Inc. (Nasdaq:NEOL) today announced that, based upon a recent Phase I study, evidence was provided that cintredekin besudotox (IL13-PE38QQR) appears to be safe and well tolerated in newly diagnosed malignant glioma patients. Results from the Phase I study will be presented at the 74th Annual Meeting of the American Association of Neurological Surgeons (AANS) held in San Francisco on...See the full content of this document
Sponsored links
